BRCA1 and BRCA2 pathogenic mutation carriers have a relative risk of PCa that is enhanced by 1.8–3.8 and 2.5 to 8.6 times, respectively, by the time they are 65 years old (Thompson et al., 2003; Agalliu et al., 2007; Leongamornlert et al., 2012). The gene discussed is BRCA1; the disease is posterior cortical atrophy.